


Welcome

- Trial registration
- Unique identification scheme
- International databases



home | my details | ISRCTN Register | mRCT | UKCTG | links | information | press

Find trials

[...Back to search results.]

ISRCTN Register

tips on searching

ISRCTN ISRCTN66434824

ClinicalTrials.gov
identifier

Registration

Public title

The RIGHT Trial: Rapid Intervention with Glyceryl trinitrate (GTN) in Hypertensive stroke Trial

New application

Scientific title

Determining the potential of ambulance-based randomised controlled trials in patients with hyperacute stroke: assessment of glyceryl trinitrate in lowering blood pressure

Updating record

Acronym

RIGHT

Information

Serial number at
source

N/A

introduction

Study hypothesis

1. To assess the feasibility of performing an ambulance-based trial in patients with hyperacute stroke, a key question for the future testing of potential interventions aimed at neuroprotection and physiological control
2. To assess the effect of glyceryl trinitrate (GTN) on blood pressure (BP) in this setting

governing board

ISRCTN FAQs

Ethics approval

Ethics approval pending from the Nottingham Research Ethics Committee 2 as of 18/02/08 (ref: 08/H0408/18).

letter of agreement

request information

Study design

Ambulance-based, single city, single-blind, randomised controlled trial with blinded outcome assessment.

guidance notes


Countries of
recruitment

United Kingdom

Disease/condition
/study domain

Acute stroke

[Print-friendly version]



Participants - inclusion criteria	1. Adult patients of either sex; greater than 40 years of age 2. Paramedic assessment of stroke on basis of positive 'Face & Arm weakness and Speech abnormality Test (FAST)' in the context of a call to a patient with a 'possible acute stroke' 3. Event less than 4 hours of onset (sleep stroke - onset as bed time) 4. High systolic BP (greater than 140 mmHg)
Participants - exclusion criteria	1. No consent/assent is available 2. GTN is indicated (e.g. concurrent angina) 3. GTN is contraindicated (e.g. dehydration, hypovolaemia) 4. Aged less than 40 years 5. Coma; Glasgow Coma Scale (GCS) score less than or equal to 8 6. History of seizures 7. Non-ambulatory pre-morbidly (modified Rankin scale of greater than 2) 8. Hypoglycaemia (if glucose tested) 9. Patients from a nursing home
Anticipated start date	01/03/2008
Anticipated end date	31/12/2009
Status of trial	Ongoing
Patient information material	Not available in web format, please use the contact details below to request a patient information sheet.
Target number of participants	80
Interventions	Transdermal GTN (5 mg) or no patch. Total duration of treatment: 7 days Total duration of follow up: 90 days
Primary outcome measure(s)	To assess the feasibility of using the ambulance service to test and deliver treatment for stroke in the hyperacute setting, will be measured as effects of GTN on blood pressure at 2 hours post-treatment.
Secondary outcome measure(s)	To assess the effects of GTN on: 1. Blood pressure 2. Pulse pressure (PP) 3. Rate pressure product (RPP) 4. Surrogate markers of efficacy in blood in the hyperacute setting Measured in hospital, day 7/discharge/death, and day 90.

Sources of funding No funding as of 19/02/08

Trial website

Publications

Contact name Prof Philip Bath

Address Division of Stroke Medicine
University of Nottingham
Clinical Sciences Building
City Hospital
Hucknall Road
Nottingham
NG5 1PB
United Kingdom
+44 (0)115 823 1765
+44 (0)115 823 1767
philip.bath@nottingham.ac.uk
University of Nottingham (UK)

Sponsor c/o Mr Paul Carlledge
Head of Research Grants and Research Innovation Services
King's Meadow Campus
Lenton Lane
Nottingham
NG7 2NR
United Kingdom
+44 (0)115 951 5670
Paul.carlledge@nottingham.ac.uk
<http://www.nottingham.ac.uk/>

Address

City/town

Zip/Postcode

Country

Tel

Fax

Email

Sponsor website: 18/02/2008

Date applied 09/05/2008

Last edited